Link Technologies Licenses Univ. of Manchester's Reagent Tech | GenomeWeb

NEW YORK (GenomeWeb News) – Link Technologies has licensed diagnostic reagent-related technology from the University of Manchester that it intends to market worldwide, the Scottish company said today.

Under the agreement with the University of Manchester Intellectual Property Limited, the firm acquired the rights to make and sell oligonucleotide reagents using the university's exciplex technology. It also will collaborate with the university to further develop the existing technology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.